You are now in the main content area
A lack of clinical efficacy has a key role to play in the majority of drug failures in clinical trials. At BioInteract, we aim to bridge the gap between laboratory research and drug discovery companies involved in the development of therapies for genetic disorders. BioInteract uses proteomics to identify the most potential drug at an early stage of preclinical studies through molecular analysis. The disease specific pre-clinical data generated by BioInteract will empower drug-discovery companies to develop a more effective drug faster.